Compugen vs Ginkgo Bioworks
CGEN and DNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGEN and DNA compare
Compugen grew revenue faster over the last twelve months (161% versus −13.2% for Ginkgo Bioworks).
Compugen keeps more of each dollar of sales as profit, with a net margin of 48.6% compared with −192% at Ginkgo Bioworks.
Compugen scores higher on the StockData Score (12 against 9 for Ginkgo Bioworks), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGEN | DNA |
|---|---|---|
| Size and price | ||
| Market cap | – | $647M |
| Share price | $2.10 | $9.61 |
| Change, 1 year | 25.0% | 15.0% |
| Change, 5 years | −55.4% | −98.2% |
| Beta (5Y) | 1.61 | 2.73 |
| Employees | 2 | 485 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 4 (better) | 2 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 4.9× |
| P/B | – | 1.6× |
| FCF yield | – | −26.8% |
| Fair value | – | $9.67 |
| Margin of safety | – | 0.61% |
| Growth | ||
| Revenue growth (TTM) | 161% (better) | −13.2% |
| Revenue growth, 5Y average | 105% (better) | 17.3% |
| Profitability | ||
| Gross margin | 87.3% | – |
| Operating margin | 43.1% (better) | −205% |
| Net margin | 48.6% (better) | −192% |
| FCF margin | 43.1% (better) | −133% |
| Return on equity | 50.9% (better) | −52.7% |
| Return on invested capital | 117% (better) | −113% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.72 (better) | 4.72 |
| Altman Z-score | – | −9.15 |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 53.7% |
| Held by insiders | 0.43% | – |
| Insider net buying, 12 months | −$126K (better) | −$5.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.7% | – |
Go deeper
- CGEN stock overview
- CGEN income statement
- CGEN valuation and score
- DNA stock overview
- DNA income statement
- DNA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.